Title: Boston Korea – Korea LegoChem, signed a contract with a global pharmaceutical company in Waltham.

Publication: Boston Korea

Date: 15 12 2012

Summary

• Agreed on co-development and license-out with AstraZeneca, a global pharmaceutical company located in Waltham, US, on 14th.

• Currently developing antibiotics that can solve serious problems of resistant bacteria.

• Vice President and Head of Infection Innovative Medicines, Manos Perros said “both companies’ expertise on antibiotics combined with our drug development ability will accelerated the successful development of a medicine.”

• Meanwhile, CEO of LegoChem, Dr. Yong Zu KIm mentioned “I hope this technological cooperation with the global pharmaceutical company will help Korea’s drug development industry.”

To view the full article (in Korean), click here ▶

About LegoChem Biosciences

LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC).